GlassScriptPhysician profile
Chad David Guetersloh
NPI 1760552202
$2,216.06
in general payments reported to CMS, 2019-2025
23 companies · $392 in 2025
The $392 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $197 · 2021: $428 · 2022: $249 · 2023: $318 · 2024: $343 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $481.80 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $322.35 | 2019-2025 | Doc Band |
| Neos Therapeutics, LP | $274.54 | 2019-2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Corium, LLC | $219.71 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $143.75 | 2025 | Jornay Pm |
| Tris Pharma INC | $111.59 | 2019-2025 | Onyda Xr |
| Genentech USA, INC. | $106.56 | 2019-2021 | |
| Adlon Therapeutics L.P. | $86.21 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $79.68 | 2020-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $54.06 | 2019-2024 | |
| Galderma Laboratories, L.P. | $52.67 | 2021 | |
| Sobi, INC | $50.20 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $42.27 | 2021-2023 | Koselugo |
| Sanofi Pasteur INC. | $28.13 | 2021-2022 | |
| Alk-Abello, INC | $25.00 | 2025 | Neffy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $23.21 | 2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $22.71 | 2025 | |
| Aytu Biopharma, INC. | $18.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.52 | 2023 | Flumist Quadrivalent |
| Kaleo, INC. | $15.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.01 | 2022 | |
| Glaxosmithkline, LLC. | $13.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Guetersloh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.